Zantac / Ranitidine (NDMA Cancer) Attorney in Minneapolis, Minnesota

Zantac Litigation in Minneapolis

Minnesota's 4-year statute of limitations for personal injury claims is more favorable than most states — giving Minneapolis-area Zantac claimants with diagnoses through 2022 active filing windows. Minnesota applies Daubert under Minn. R. Evid. 702. Minneapolis's sophisticated healthcare sector (Medtronic, UnitedHealth, Fairview) means many claimants have comprehensive employer pharmacy benefit records. National counsel recommend Delaware Superior Court as primary filing venue. The federal Zantac MDL (No. 2924, S.D. Florida) was largely dismissed in 2022 after Judge Robin Rosenberg excluded plaintiffs' causation experts under Daubert. However, the Delaware Superior Court under Judge Vivian Medinilla continues to actively hear Zantac cases and has allowed causation experts to proceed. Defendants Sanofi, Boehringer Ingelheim, GSK, and Pfizer are all actively litigating in Delaware. For most claimants, filing in Delaware Superior Court through national plaintiffs' counsel is now the primary path forward.

Resources for Minneapolis Zantac Claimants

Minneapolis-area Zantac claimants should gather pharmacy records from Cub Foods (Supervalu), Walgreens, CVS, and employer pharmacy benefit programs. University of Minnesota Masonic Cancer Center and Allina Health records documenting bladder, esophageal, stomach, or colorectal cancer are critical evidence. Minnesota's 4-year SOL is among the most favorable in the Midwest — but prompt consultation with qualified Zantac counsel is still essential.